New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:53 EDTAMGN, NVS, BA, BLK, DISH, QIHU, STO, SSNLF, CS, IBM, UBS, AAPL, AIGOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Dish (DISH) to pull LightSquared bid...Lenders use social media to check borrowers' creditworthiness...A U.S.-EU trade war could break out over online privacy...Hong Kong stock exchange to rethink IPOs after Alibaba views...AIG (AIG) extends expiration of tax asset plan to 2017...REUTERS: Credit Suisse (CS) bets on a turnaround for money-losing U.S. brokerage...BlackRock (BLK), NY attorney general agreement ends analyst surveys...Apple (AAPL), Samsung (SSNLF) CEOs to attend mediation in U.S. patent fight...Boeing (BA) machinists want new vote, allege unfair labor practices...BLOOMBERG: Regulators consider Volcker exemption for smaller banks' CDOs...UBS (UBS) may spin off investment bank...As Norway loosens control, Statoil (STO) looks abroad for deals (Businessweek)...Samsung (SSNLF) sees Galaxy S5 by April, studies eye scanner...FINANCIAL TIMES: Novartis (NVS) facing criminal investigation in Japan over drug advertising...IBM (IBM) to create new $1B Watson business unit...CHINA DAILY: Qihoo 360 (QIHU) denies Alibaba interested in investing...SFGATE: Explosion reported at Amgen (AMGN).
News For DISH;AIG;CS;BLK;AAPL;SSNLF;BA;UBS;STO;NVS;IBM;QIHU;AMGN From The Last 14 Days
Check below for free stories on DISH;AIG;CS;BLK;AAPL;SSNLF;BA;UBS;STO;NVS;IBM;QIHU;AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 7, 2014
14:06 EDTAAPLApple slips to lows of the day, levels to watch
Shares were last at $522.56, just off the session low. At current price, next support is at $517.35. Resistance is at $527.67.
13:53 EDTQIHUQihoo 360 Technology volatility increases as shares pull back to six-week low
Subscribe for More Information
13:08 EDTUBSPanel rules UBS unit to pay $5.4M to ex-broker, Reuters says
A Financial Industry Regulation Authority arbitration panel ruled that a unit of UBS has to pay $5.4M to an ex-broker to settle a dispute which stemmed from the sale of Lehman structured notes to his clients, reported Reuters. Reference Link
13:05 EDTSSNLFAnalyst says semiconductor stocks attractive after decline
Subscribe for More Information
12:21 EDTBABoeing now sees completing C-17 production in mid-2015
Boeing adjusted slightly the timing for ending C-17 Globemaster III production and closing its Long Beach, Calif., C-17 final assembly facility after a successful two-decade production run of the world's premier airlifter.Based on current market trends and the timing of expected orders, Boeing anticipates completing C-17 production in mid-2015, an adjustment of approximately three months from an initial estimate of late 2015. The company announced plans to end C-17 production in September 2013. Boeing expects inventory–related charges of approximately $50M, which will be recorded in Q1, as a result of this announcement.
10:10 EDTIBMAnalyst sees 'golden' opportunity after software stocks decline
Subscribe for More Information
10:00 EDTSTOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:34 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:45 EDTAAPLInvenSense price target raised to $27 from $20 at Pacific Crest
Subscribe for More Information
07:51 EDTAAPLApple sent iTV panel samples from Korean display maker, Korea Herald says
Subscribe for More Information
07:37 EDTAAPL, SSNLFApple considered dumping long-time ad agency, WSJ reports
Subscribe for More Information
07:33 EDTSSNLFFLIR Systems hires Travis Merrill as Chief Marketing Officer
Subscribe for More Information
07:27 EDTNVSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
07:16 EDTAAPLRetailers muscle into competitive mobile payment market, Reuters says
Subscribe for More Information
07:03 EDTAIGAIG loss ratio to continue to improve, says Bernstein
Subscribe for More Information
06:58 EDTCS, UBSDark markets could cause more harm than high-frequency trading, Reuters says
After a book by financial author Michael Lewis sparked worries that high-speed traders have been rigging the U.S. stock market, former regulators and academics say a more serious threat to investors could be the increasing amount of trading that happens outside of exchanges, reported Reuters. Top internalizers include units of KCG Holdings (KCG), Citadel, UBS (UBS), and Citigroup (C). Dark pool operators include Credit Suisse (CS) and Morgan Stanley (MS). In an attempt to earn back some of the retail orders, exchanges such as IntercontinentalExchange Group's (ICE) New York Stock Exchange, Nasdaq (NDAQ), and BATS Global Markets, have allowed brokerages to place dark pool-style orders on their platforms, with the trade hidden until after it is executed. Reference Link
06:36 EDTAAPLApple's sales force worried about iPhone outlook, Re/code reports
Apple's (AAPL) sales force has been worried about weakness in the iPhone's market share, amid strong competition from Google's (GOOG) Android operating system, a document presented in a court case showed, Re/code reported on Friday. According to the internal Apple document, the only portions of the smartphone market showing growth were large devices costing more than $300 or devices that cost less than $300, the website stated. Reference Link
06:28 EDTCSNew York launches probe of Credit Suisse, NY Times says
Subscribe for More Information
05:43 EDTSTOStatoil downgraded to Sell from Neutral at Goldman
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use